Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Некоторые прогностические факторы при современной терапии хронического лимфолейкоза
Некоторые прогностические факторы при современной терапии хронического лимфолейкоза
Т.Е.Бялик, Л.Ю.Гривцова, А.И.Карселадзе, Т.П.Загоскина, С.С.Бессмельцев, М.А.Волкова. Некоторые прогностические факторы при современной терапии хронического лимфолейкоза. Онкология. 2006; 4: 16-19.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Schulz H, Klein S, Rehwald U et al. Phase 2 study of combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 2002; 100: 3115–20.
2. Keating M, Plunkett W, Х Brain S et. al. Combination therapy in CLL. Leukemia 2000, Program and abstract book. p. 26, abstr. S25.
3. Calligalis-Cappio F. Biology of chronic lymphocytic leukemia. Reu Clin Exp Heamatol 2000; 4 (1): 5–22.
4. Byrd J. A new twist for CD38 antigen expression in CLL. Blood 2005; 105 (8): 3002–3.
5. Damle RN, Wasil T, Fais F et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94 (6): 1840–7.
6. Hamblin TJ, Orchard JA, Ibbotson RE et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002; 99 (3): 1023–9.
7. Lin K, Sherrington PD, Dennis M et al. Relatioship between p53 dysfunction, CD38 expression, and Ig VH mutation in chronic lymphocytic leukemia. Blood 2002; 100 (4): 1404–9.
8. Juliusson G, Oscier DG, Fitcher M et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med 1990; 323: 720–4.
9. Dohner H, Stilgenbauer S, Benner A et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910–6.
10. Goorha S, Glenn MJ, Drozd-Borysiuk E, Chen Z. A set of commercially available fluorescent in-situ hybridization probes efficiently detects cytogenetic abnormalities in patients with chronic lymphocytic leukemia. Genet Med 2004; 6: 48–53.
2. Keating M, Plunkett W, Х Brain S et. al. Combination therapy in CLL. Leukemia 2000, Program and abstract book. p. 26, abstr. S25.
3. Calligalis-Cappio F. Biology of chronic lymphocytic leukemia. Reu Clin Exp Heamatol 2000; 4 (1): 5–22.
4. Byrd J. A new twist for CD38 antigen expression in CLL. Blood 2005; 105 (8): 3002–3.
5. Damle RN, Wasil T, Fais F et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94 (6): 1840–7.
6. Hamblin TJ, Orchard JA, Ibbotson RE et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002; 99 (3): 1023–9.
7. Lin K, Sherrington PD, Dennis M et al. Relatioship between p53 dysfunction, CD38 expression, and Ig VH mutation in chronic lymphocytic leukemia. Blood 2002; 100 (4): 1404–9.
8. Juliusson G, Oscier DG, Fitcher M et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med 1990; 323: 720–4.
9. Dohner H, Stilgenbauer S, Benner A et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910–6.
10. Goorha S, Glenn MJ, Drozd-Borysiuk E, Chen Z. A set of commercially available fluorescent in-situ hybridization probes efficiently detects cytogenetic abnormalities in patients with chronic lymphocytic leukemia. Genet Med 2004; 6: 48–53.
Авторы
Т.Е.Бялик, Л.Ю.Гривцова, А.И.Карселадзе, Т.П.Загоскина, С.С.Бессмельцев, М.А.Волкова
РОНЦ им. Н.Н.Блохина РАМН, Москва; НИИ гематологии и переливания крови, Киров;
Российский НИИ гематологии и трансфузиологии, Санкт-Петербург
РОНЦ им. Н.Н.Блохина РАМН, Москва; НИИ гематологии и переливания крови, Киров;
Российский НИИ гематологии и трансфузиологии, Санкт-Петербург
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.